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ABSTRACT
Broad-spectrum antibiotics are often associated with a relatively high risk of Clostridium difﬁcile infection
(CDI). However, exceptions to this rule, e.g., piperacillin–tazobactam, show that marked inhibition of
gut ﬂora is not synonymous with CDI risk. Tigecycline has marked broad-spectrum activity that
includes Gram-positive and Gram-negative facultative and obligate anaerobes. Antibiotic susceptibility,
gut model and clinical trial data suggest that tigecycline is associated with a relatively low risk of CDI.
Further clinical data should be obtained to conﬁrm the results of these initial studies.
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Tigecycline has a unique broad spectrum of
activity that includes Gram-positive and Gram-
negative facultative and obligate anaerobes,
tetracycline-resistant or multiply-resistant strains,
and atypical bacteria [1,2]. Tigecycline has inher-
ently poor activity against Proteus spp., Providen-
cia spp., Morganella spp. and Pseudomonas spp.
Such wide-ranging activity, combined with a
large distribution volume and extensive tissue
penetration, means that there is potential for
marked inhibition of human microbial ﬂora.
Taken simplistically, these features could be
interpreted as equating to a high risk of second-
ary infection by microbes such as Clostridium
difﬁcile that may be suppressed by intact gut
ﬂora. However, interpreting the signiﬁcance of
antibiotic-induced changes in gut ﬂora species is
hindered by large inter-subject variability in
response and baseline counts [2]. Gut ﬂora
inhibition alone is not sufﬁcient to permit growth
of C. difﬁcile and toxin production, and such
inhibition is not synonymous with the risk of
C. difﬁcile infection (CDI) [4,5]. For example,
piperacillin–tazobactam causes severe depletion
of gut ﬂora, but neither germination of C. difﬁcile
nor cytotoxin production [4], and has a relatively
low risk of inducing CDI [6,7]. Nevertheless,
antibiotic activity against C. difﬁcile may affect the
risk of CDI. Strains susceptible to gut concentra-
tions of antibiotic are unlikely to proliferate, but
may remain as quiescent spores. However, a
clindamycin-resistant C. difﬁcile strain caused
outbreaks of CDI associated with use of clinda-
mycin [8], and recent reports have implicated
ﬂuoroquinolone-resistant C. difﬁcile strains in
CDI, although other virulence traits and trans-
mission risk-factors may also be important [9,10].
In-vitro batch culture experiments to investi-
gate the effects of antimicrobial exposure tend not
to correlate with clinical observations concerning
the risk of CDI [11,12]. An inability to model CDI
in a simple batch culture model probably reﬂects
multifactorial pathogenesis and the crucial role of
the bacterial growth cycle in toxin expression [13].
Data from hamster model experiments may not
reﬂect gut microﬂora or antibiotic exposure phar-
macokinetics in human patients [14,15], and
human volunteer studies can only provide limited
data concerning the risk of CDI, not least because
they invariably involve healthy, young subjects
who are not normally colonised by or exposed
to C. difﬁcile. A human gut model using a
triple-stage chemostat has addressed some of
the deﬁciencies of other approaches by pooling
C. difﬁcile-negative faeces from healthy, elderly
individuals [4,5,16], and then measuring C. difﬁcile
growth and, speciﬁcally, germination leading to
sporulation with toxin expression, as well as gut
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ﬂora changes, following exposure to antibiotic.
C. difﬁcile behaviour in this model correlates with
clinical experience of CDI risk following antibiotic
exposure [4,6,7,16], although the effects of host
immunity were not examined.
Well-controlled clinical studies are required to
investigate the risk of CDI, but most studies are
retrospective and poorly controlled for antibiotic
duration or polypharmacy, and particularly for
exposure to C. difﬁcile [17,18]. Furthermore, the
results obtained may not be applicable to other
scenarios in which patient factors (age, frailty,
co-morbidities, humoral immunity) or strain-
speciﬁc determinants (antibiotic susceptibility,
toxin production) may alter the risk of infection.
The propensity of new antimicrobial agents to
induce CDI is often unclear. Pre-licensing studies
are not normally performed in C. difﬁcile-ende-
mic settings, and only rarely include patients at
high risk of CDI. Also, protocol variability
means that some CDI cases may not be recorded
as such.
Tigecycline is highly active against vegetative
C. difﬁcile (MIC90s 0.032–0.12 mg ⁄L) [1,2,19]. It is
important to distinguish between clonal and
distinct C. difﬁcile isolates when testing suscepti-
bility. Tigecycline MICs were uniformly
0.06 mg ⁄L for 39 C. difﬁcile isolates, including 19
distinct PCR ribotypes and 15 ribotype 027 iso-
lates [19]. This degree of antibiotic susceptibility
in C. difﬁcile is uncommon, especially to broad-
spectrum antibiotics. Ampicillin, cefotaxime,
ciproﬂoxacin, meropenem and piperacillin–tazo-
bactam have MIC90s for C. difﬁcile of c. 1, >64, 32,
4 and 4 mg ⁄L, respectively [20,21]. MIC90s of the
two main treatment options for CDI, metronida-
zole and vancomycin, are 1–2 mg ⁄L [22]. The
median faecal tigecycline concentration in adult
volunteers was 5.6 mg ⁄kg on day 8 of adminis-
tration [3]. Thus, antibiotic concentrations in the
large bowel during treatment far exceed the
tigecycline MIC for C. difﬁcile. Highly tigecy-
cline-susceptible C. difﬁcile strains are unlikely to
proliferate, even if gut ﬂora inhibition occurs. This
does not preclude the possibility that C. difﬁcile
spores could remain in the colon until antibiotic
levels decrease, and then germinate and produce
toxin subsequently.
In a gut model, all measured components of the
gut microﬂora were inhibited by in-vivo levels of
tigecycline (4.7–7.4 mg ⁄L), including marked
reductions in biﬁdobacteria and bacteroides
(‡107 CFU ⁄mL) [19]. Notably, in contrast to this
large and persistent effect on bacteroides, only
minor reductions were seen in volunteers [3].
Despite the marked effects on gut ﬂora, consistent
with broad-spectrum tigecycline activity, antibi-
otic exposure was not followed by germination
and ⁄ or proliferation, and did not induce toxin
production by either of two epidemic C. difﬁcile
strains [19]. Toxin production in the gut model is
usually coincident with antibiotic concentrations
decreasing below the MIC for C. difﬁcile [5].
Antibiotic concentrations were below the limits
of detection (1 mg ⁄L) in the model within 6 days
of cessation of tigecycline instillation and, by
extrapolation, would have reached sub-MIC lev-
els for C. difﬁcile about 1 week before the end of
the experiments [19]. Thus, while there was
opportunity for late toxin production to occur
following decline of tigecycline levels to sub-
inhibitory levels, this did not occur.
Marked reductions in the numbers of lacto-
bacilli and biﬁdobacteria, but usually a minimal
impact on bacteroides, were seen following tige-
cycline administration to healthy volunteers [3].
As expected, counts of enterococci and Escherichia
coli were also reduced signiﬁcantly. However, the
numbers of other enterobacteria increased,
including Klebsiella and Enterobacter spp.; indeed,
six of 12 volunteers were colonised by tigecycline-
resistant Klebsiella pneumoniae and Enterobacter
cloacae strains on day 8. There was considerable
inter-subject variation in tigecycline faecal con-
centrations; bioassay levels on day 8 of tigecycline
varied almost ﬁve-fold (3.0–14.1 mg ⁄ kg). None of
the volunteers was colonised by C. difﬁcile during
the 31-day study, but it is not possible to deter-
mine the signiﬁcance of these observations with
respect to the risk of CDI.
In four phase 3 studies, nausea and vomiting
occurred signiﬁcantly more often in tigecycline
recipients (n = 1415; overall 29.5% and 19.7%,
respectively) than in comparator patients
(n = 1382; 15.8% and 10.8%, respectively) (both
p <0.001) [23]. Diarrhoea was a treatment-emer-
gent adverse event in similar proportions for
tigecycline and comparator recipients (12.7% and
10.8%, respectively; p 0.127). Possible CDI cases
in all completed phase 2 (n = 4) and phase 3
(n = 9, seven of which were blinded) studies,
involving 2402 tigecycline and 1892 comparator
(825 imipenem, 589 vancomycin ± aztreonam, 422
levoﬂoxacin, 52 ciproﬂoxacin and four linezolid)
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recipients, have recently been reviewed [24]. For a
diagnosis of antibiotic-associated CDI, symptoms
(diarrhoea, abdominal pain ⁄distension, colitis)
had to be absent at baseline, but last for ‡48 h.
Of nine possible cases of CDI, ﬁve received
tigecycline and three received a comparator anti-
biotic (two imipenem, one levoﬂoxacin) (Table 1).
One possible case received tigecycline (days 1–5)
and then an oral comparator agent (levoﬂoxacin,
days 6–10). As CDI symptoms developed on day
14, speciﬁc antibiotic causality could not be
established. The overall rates of CDI were
5 ⁄ 2402 (0.21%) for tigecycline and 3 ⁄ 1892
(0.16%) for comparator agents (no signiﬁcant
difference). CDI cases frequently received non-
study antibiotics (median three) before the onset
of symptoms, making it impossible to be certain
which agent(s) may have induced CDI. The cases
were mild–moderate in severity, and (where
follow-up data were available) the patients recov-
ered.
In conclusion, the marked broad-spectrum
activity of tigecycline does not appear to result
in an increased risk of CDI. Broad-spectrum
agents are often (e.g., cephalosporins), but not
always (e.g., piperacillin–tazobactam), associated
with a relatively high risk of CDI [6,7,25].
Formulary changes and restrictive prescribing
to limit the use of high-risk antibiotics have been
used successfully to reduce CDI [25]. Of course,
low-risk antibiotics may still either induce or be
implicated in CDI, especially in patients exposed
to long-duration or multiple antimicrobial
agents. Further clinical data are needed to
Table 1. Possible cases of Clostridium difﬁcile infection (CDI) associated with tigecycline or comparator agents
Patient details Symptoms
Antibiotic history
(number of days
before CDI onset)
CDI onset in relation
to tigecycline ⁄
comparator exposure
Treatment and
CDI outcome
Case A Male aged 44 years.
Surgery for perforated
appendix
Diarrhoea for 5 days Cefoxitin (5),
gentamicin (4)
metronidazole (4),
tigecycline
4 days after tigecycline
started
Treated with 14 days
of metronidazole.
Resolved
Case B Male aged 79 years.
Peritonitis secondary to perforation
of large intestine
Diarrhoea of unknown
duration, abdominal
pain
Ceftriaxone ·2
(27 and 6),
levoﬂoxacin ·2
(20 and 6),
vancomycin (27),
tigecycline
17 days after 10-day
course of tigecycline
ended
Treated with
metronidazole.
Not stated
Case C Male aged 23 years.
Road trafﬁc accident
with severe
abdominal injuries and
pneumonia
Diarrhoea for 5 days
(but was present at
baseline)
Cefazolin (10),
piperacillin–
tazobactam ·2
(8 and 4),
gentamicin (4),
vancomycin (4),
tigecycline
5 days after tigecycline
started
Treated with 4 days
of vancomycin.
Resolved
Case D Male aged 72 years
Multiple medical co-morbidities, and
MRSA bacteraemia
Diarrhoea of unknown
duration
Azithromycin (23),
levoﬂoxacin (23),
vancomycin (23),
ciproﬂoxacin
from (9),
minocycline (17),
rifampicin (0),
tigecycline
12 days after 6-day
course of tigecycline
ended
Treated with
metronidazole.
Not stated
Case E Female aged 73 years.
Intra-abdominal
abscess, drained
percutaneously
Diarrhoea of unknown
duration, pseudo-membranous
colitis
Vancomycin ·2
(39 and 37),
ciproﬂoxacin (37),
metronidazole (37),
tigecycline
30 days after 8-day
course of tigecycline
ended
Not stated
Case F Female aged 42 years.
Surgery (small bowel
resection and drainage)
for abscess associated
with appendicitis
Diarrhoea for 5 days Ciproﬂoxacin (15),
cefozil (13),
cefoxitin (13),
imipenem
7 days after 7-day
course of imipenem
ended
Treated with 4 days
of vancomycin.
Not stated
Case G Male aged 73 years.
Surgery for complicated
appendicitis
Diarrhoea for 13 days Gentamicin (6),
metronidazole (6),
ertapenem (5),
imipenem
5 days after imipenem
started
Treated with 6 and
12 days of
vancomycin, and
9 days of
metronidazole.
Not stated
Case H Female aged 78 years.
Community-acquired
pneumonia
Diarrhoea for 18 days No other recent
antibiotics before
receiving
levoﬂoxacin
10 days after levoﬂoxacin
started
Treated with 12 days
of metronidazole.
Not stated
MRSA, methicillin-resistant Staphylococcus aureus.
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conﬁrm accumulating data suggesting that tige-
cycline is associated with a relatively low risk of
CDI.
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